Clinical Trial Search

Phase 2 N=360 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years

Healthy

Primary: Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination Dose by Severity — 7; 0; 14; 3 participants

Takeda Results Mar 2018 8.1% serious AE View details

N/A N=29 Effect of Intra-Oral Photobiomodulation on Orthodontic Treatment Time

Malocclusion

Primary: Overall Orthodontic Treatment Time for OrthoPulse™ and Non-OrthoPulse™ Treated Patients. — 19.0; 21.2 months

Biolux Research Holdings, Inc. Results Mar 2018 0.0% serious AE View details

Phase 2 N=45 MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

Diffuse Large B-Cell Lymphoma · Transformed Follicular Lymphoma · Mantle Cell Lymphoma

Primary: Number of Participants With Clinically Significant Vital Signs Findings (Treatment Related and Unrelated) [Phase 1] — 0; 0; 3; 1 participants

Millennium Pharmaceuticals, Inc. Results Mar 2018 48.9% serious AE View details

Phase 2 N=31 MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma

Ovarian Carcinoma

Primary: Combined Best Overall Response Rate Based on Investigator Assessment — 0; 12 percentage of participants

Millennium Pharmaceuticals, Inc. Results Mar 2018 35.5% serious AE View details

Phase 3 N=4,481 Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

Arthritis, Rheumatoid

Primary: Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports — 991; 2963; 3954; 159 Number of…

Pfizer Results Mar 2018 29.9% serious AE View details

N/A N=127 A Comparison of Ultrasound Guided Transversus Abdominis Plane Nerve Block Techniques

Crohn's Disease · Inflammatory Bowel Disease · Postoperative Pain

Primary: Morphine Requirement — 31.4; 39; 22.8 mg

Cedars-Sinai Medical Center Results Mar 2018 0.0% serious AE View details

Phase 2 N=400 A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

MENINGOCOCCAL INFECTION

Primary: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >= Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria…

Pfizer Results Mar 2018 1.5% serious AE View details

N/A N=200 A Randomized Comparison of Transcervical Foley Bulb With Vaginal Misoprostol to Vaginal Misoprostol Alone for Induction of Labor

Pregnancy

Primary: The Time Interval From Induction to Delivery: All Participants — 20.97; 16.27 hours

St. Luke's-Roosevelt Hospital Center Results Mar 2018 0.0% serious AE View details

Phase 2 N=98 Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm. — 96.9; 93.9 percentage of participants — p=0.5

Gilead Sciences Results Mar 2018 6.3% serious AE View details

N/A N=118 TEOSYAL® RHA Ultra Deep and Perlane-L® for the Correction of Nasolabial Folds

Nasolabial Folds, Wrinkles

Primary: Non-inferiority of the Delta of the WSRS Score Between W24 and Baseline for TEOSYAL® RHA Ultra Deep Versus Perlane-L® for the Correction of Moderate to Severe…

Teoxane SA Results Mar 2018 2.5% serious AE View details

N/A N=203 Beverages and Societal Health

Cardiovascular Disease, Obesity

Primary: Ratio of Serum Triglyceride to HDL-cholesterol Concentration (TG:HDLC) — 1.46; 1.19; 1.45 ratio of Triglycerides-to-HDL

Boston Children's Hospital Results Mar 2018 1.5% serious AE View details

Phase 4 N=101 Skin and Soft Tissue Infection (SSTI) Study

Skin Diseases, Infectious · Soft Tissue Infections

Primary: Number of Participants With a Clinical Cure — 45; 42 Participants — p=0.71

The University of Texas Health Science Center at… Results Mar 2018 0.0% serious AE View details

Phase 2 N=131 A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve

Infertility · Ovulation Induction

Primary: Mean Number of Metaphase II (M-II) Oocytes Retrieved — 6.7; 7.0 M-II oocytes

Merck KGaA, Darmstadt, Germany Results Mar 2018 0.0% serious AE View details

N/A N=36 A Double Blind Clinical Trial of DCS for Food Anxiety

Anorexia and Bulimia Nervosa

Primary: Anxiety as Measured by the Subjective Units of Distress (Ranging From 1 to 100). — 52.395; 58.983 Units on a scale

Washington University School of Medicine Results Mar 2018 0.0% serious AE View details

Phase 2 N=30 Treatment of Rett Syndrome With Recombinant Human IGF-1

Rett Syndrome

Primary: Rett Syndrome Behavior Questionnaire (RSBQ) - Fear/Anxiety Subscale — 4.00; 5.00; 5.00; 3.00 units on a scale

Boston Children's Hospital Results Mar 2018 11.1% serious AE View details